AMIC recently announced that it has begun producing fluorine-18 and that it has signed a Letter of Intent to purchase the Center of Molecular Research of Moscow, Russia. The company intends to increase production centers, seek additional partnerships with universities and national laboratories, and expand its role as a national supplier of medical isotopes to researchers at major universities, pharmaceutical companies, and international markets.
``The restructuring of roles marks an effort to best meet the current needs of the company, as we focus on establishing AMIC as a leader in the manufacturing and distribution of medical isotopes,'' said James C. Katzaroff. ``We have gained traction in achieving our objectives, and we believe that this shift will help us meet new goals in the future. We look forward to encountering fresh opportunities in these positions.''
``I am looking forward to my new position as president,'' said Mr. Stokes. ``AMIC has reached significant milestones in recent months, and we expect 2008 to be a tremendous year of development as AMIC continues its focus on expanded partnerships with the DOE, various national labs, and University programs.''
Nuclear Medicine, which employs the use of medical isotopes to diagnose and treat many life-threatening diseases, such as heart disease and cancer, is one of the fastest growing segments in the health industry today. In the United States more than twelve million nuclear medicine procedures are performed annually. According to the Citizens for Medical Isotopes, the demand for medical isotopes is projected to grow in the range of 8% to 20% per year for the next twenty years.
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (AMIC) is a medical isotope production company engaged in the production and distribution of medical isotopes and medical isotope in vivo delivery systems for advanced diagnostic and non-surgical therapeutic application. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until now, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website, http://www.isotopeworld.com.
The Advanced Medical Isotope Corporation logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=5139
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words ``may,'' ``will,'' ``should,'' ``plans,'' ``explores,'' ``expects,'' ``anticipates,'' ``continue,'' ``estimate,'' ``project,'' ``intend,'' and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.
Contact:
Advanced Medical Isotope Corporation James C. Katzaroff 509-736-4000
The Investor Relations Group Erika Moran Lynn Granito Steven Melfi 212-825-3210
Source: Advanced Medical Isotope Corporation
